A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

Trial Profile

A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms AMAGINE-1
  • Sponsors Amgen
  • Most Recent Events

    • 20 Jul 2017 According to a LEO Pharma media release, European Commission has granted marketing authorisation for Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy.
    • 19 May 2017 According to an AstraZeneca media release, the CHMPs positive opinion on brodalumab will now be reviewed by the European Commission and the final decision is applicable to all EU and European Economic Area countries (Iceland, Liechtenstein and Norway).
    • 19 May 2017 According to a LEO Pharma media release, Professor Kristian Reich was Principal Investigator of the AMAGINE trials programme.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top